Exelixis, Inc. (EXEL)
64.53
-0.78
(-1.19%)
USD |
NASDAQ |
Oct 23, 16:00
64.56
+0.03
(+0.05%)
After-Hours: 20:00
Exelixis Market Cap : 16.06B for Oct. 23, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| October 23, 2026 | 16.06B |
| October 22, 2026 | 16.25B |
| October 21, 2026 | 16.07B |
| October 20, 2026 | 16.03B |
| October 19, 2026 | 15.60B |
| October 16, 2026 | 15.49B |
| October 15, 2026 | 15.64B |
| October 14, 2026 | 15.18B |
| October 13, 2026 | 14.81B |
| October 12, 2026 | 14.89B |
| October 09, 2026 | 14.90B |
| October 08, 2026 | 14.69B |
| October 07, 2026 | 14.54B |
| October 06, 2026 | 14.52B |
| October 05, 2026 | 14.65B |
| October 02, 2026 | 14.53B |
| October 01, 2026 | 14.42B |
| September 30, 2026 | 14.54B |
| September 29, 2026 | 14.60B |
| September 28, 2026 | 14.53B |
| September 25, 2026 | 14.48B |
| September 24, 2026 | 14.42B |
| September 23, 2026 | 14.12B |
| September 22, 2026 | 14.47B |
| September 21, 2026 | 14.24B |
| Date | Value |
|---|---|
| September 18, 2026 | 14.52B |
| September 17, 2026 | 14.56B |
| September 16, 2026 | 14.13B |
| September 15, 2026 | 14.16B |
| September 14, 2026 | 13.99B |
| September 11, 2026 | 13.97B |
| September 10, 2026 | 14.29B |
| September 09, 2026 | 14.52B |
| September 08, 2026 | 14.35B |
| September 04, 2026 | 14.69B |
| September 03, 2026 | 14.72B |
| September 02, 2026 | 14.57B |
| September 01, 2026 | 14.16B |
| August 31, 2026 | 13.60B |
| August 28, 2026 | 13.55B |
| August 27, 2026 | 13.75B |
| August 26, 2026 | 13.96B |
| August 25, 2026 | 14.12B |
| August 24, 2026 | 13.58B |
| August 21, 2026 | 13.46B |
| August 20, 2026 | 13.36B |
| August 19, 2026 | 13.54B |
| August 18, 2026 | 13.22B |
| August 17, 2026 | 13.02B |
| August 14, 2026 | 12.75B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.96B |
| BioMarin Pharmaceutical, Inc. | 10.83B |
| Cytokinetics, Inc. | 8.496B |
| Emergent BioSolutions, Inc. | 319.60M |
| Gilead Sciences, Inc. | 193.65B |
Market Cap Related Metrics
| PE Ratio | 20.27 |
| PS Ratio | 7.165 |
| PEG Ratio | 0.3846 |
| Price to Book Value | 8.711 |
| Price to Free Cash Flow | 14.89 |
| Price | 64.53 |
| Earnings Yield | 4.93% |
| PEGY Ratio | 0.3846 |
| Operating PE Ratio | 17.59 |
| Normalized PE Ratio | 19.95 |